Industrial - Machinery
Compare Stocks
5 / 10Stock Comparison
BURU vs IPGP vs LYRA vs NPKI vs MKSI
Revenue, margins, valuation, and 5-year total return — side by side.
Semiconductors
Biotechnology
Oil & Gas Equipment & Services
Hardware, Equipment & Parts
BURU vs IPGP vs LYRA vs NPKI vs MKSI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Industrial - Machinery | Semiconductors | Biotechnology | Oil & Gas Equipment & Services | Hardware, Equipment & Parts |
| Market Cap | $1M | $4.31B | $781K | $1.30B | $20.25B |
| Revenue (TTM) | $109K | $1.04B | $600K | $287M | $4.07B |
| Net Income (TTM) | $-63M | $29M | $-33M | $36M | $327M |
| Gross Margin | -392.0% | 37.6% | 50.0% | 35.2% | 45.2% |
| Operating Margin | -116.1% | 0.3% | -58.2% | 11.4% | 14.8% |
| Forward P/E | — | 62.6x | — | 29.3x | 30.4x |
| Total Debt | $9M | $0.00 | $34M | $37M | $4.69B |
| Cash & Equiv. | $209K | $404M | $41M | $5M | $675M |
BURU vs IPGP vs LYRA vs NPKI vs MKSI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 24 | May 26 | Return |
|---|---|---|---|
| Nuburu, Inc. (BURU) | 100 | 10.2 | -89.8% |
| IPG Photonics Corpo… (IPGP) | 100 | 130.2 | +30.2% |
| Lyra Therapeutics, … (LYRA) | 100 | 9.7 | -90.3% |
| NPK International I… (NPKI) | 100 | 184.6 | +84.6% |
| MKS Inc. (MKSI) | 100 | 264.7 | +164.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BURU vs IPGP vs LYRA vs NPKI vs MKSI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BURU lags the leaders in this set but could rank higher in a more targeted comparison.
IPGP is the clearest fit if your priority is income & stability.
- Dividend streak 1 yrs, beta 1.80
LYRA ranks third and is worth considering specifically for sleep-well-at-night and defensive.
- Lower volatility, beta 0.65, current ratio 3.41x
- Beta 0.65, current ratio 3.41x
- Beta 0.65 vs MKSI's 2.64
NPKI carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 27.4%, EPS growth 124.0%, 3Y rev CAGR 12.8%
- 27.4% revenue growth vs BURU's -92.7%
- Better valuation composite
- 12.4% margin vs BURU's -578.5%
MKSI is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 7.5% 10Y total return vs NPKI's 91.5%
- 0.3% yield; the other 4 pay no meaningful dividend
- +306.1% vs LYRA's -91.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.4% revenue growth vs BURU's -92.7% | |
| Value | Better valuation composite | |
| Quality / Margins | 12.4% margin vs BURU's -578.5% | |
| Stability / Safety | Beta 0.65 vs MKSI's 2.64 | |
| Dividends | 0.3% yield; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +306.1% vs LYRA's -91.6% | |
| Efficiency (ROA) | 8.5% ROA vs BURU's -479.1% |
BURU vs IPGP vs LYRA vs NPKI vs MKSI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
BURU vs IPGP vs LYRA vs NPKI vs MKSI — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
NPKI leads in 2 of 6 categories
MKSI leads 1 • IPGP leads 1 • BURU leads 0 • LYRA leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
NPKI leads this category, winning 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MKSI is the larger business by revenue, generating $4.1B annually — 37388.0x BURU's $108,912. NPKI is the more profitable business, keeping 12.4% of every revenue dollar as net income compared to BURU's -578.5%. On growth, IPGP holds the edge at +16.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $108,912 | $1.0B | $600,000 | $287M | $4.1B |
| EBITDAEarnings before interest/tax | -$39M | $55M | -$34M | $53M | $945M |
| Net IncomeAfter-tax profit | -$63M | $29M | -$33M | $36M | $327M |
| Free Cash FlowCash after capex | -$8M | $8M | -$34M | $32M | $401M |
| Gross MarginGross profit ÷ Revenue | -3.9% | +37.6% | +50.0% | +35.2% | +45.2% |
| Operating MarginEBIT ÷ Revenue | -116.1% | +0.3% | -58.2% | +11.4% | +14.8% |
| Net MarginNet income ÷ Revenue | -578.5% | +2.8% | -54.9% | +12.4% | +8.0% |
| FCF MarginFCF ÷ Revenue | -69.8% | +0.8% | -56.8% | +11.1% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +16.6% | -87.2% | +15.9% | +15.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +82.1% | -54.4% | -17.8% | 0.0% | +53.2% |
Valuation Metrics
Evenly matched — LYRA and NPKI each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 36.8x trailing earnings, NPKI trades at a 74% valuation discount to IPGP's 139.2x P/E. On an enterprise value basis, NPKI's 18.5x EV/EBITDA is more attractive than IPGP's 48.9x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1M | $4.3B | $781,126 | $1.3B | $20.2B |
| Enterprise ValueMkt cap + debt − cash | $11M | $3.9B | -$5M | $1.3B | $24.3B |
| Trailing P/EPrice ÷ TTM EPS | -0.04x | 139.22x | -0.31x | 36.75x | 68.83x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 62.62x | — | 29.34x | 30.36x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 48.90x | — | 18.49x | 26.70x |
| Price / SalesMarket cap ÷ Revenue | 9.14x | 4.30x | 0.51x | 4.71x | 5.15x |
| Price / BookPrice ÷ Book value/share | — | 2.04x | 2.47x | 3.77x | 7.49x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 49.58x | 40.74x |
Profitability & Efficiency
NPKI leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
MKSI delivers a 12.2% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-10 for LYRA. NPKI carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to LYRA's 2.97x. On the Piotroski fundamental quality scale (0–9), NPKI scores 7/9 vs BURU's 1/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +1.4% | -10.3% | +10.3% | +12.2% |
| ROA (TTM)Return on assets | -4.8% | +1.2% | -60.2% | +8.5% | +3.7% |
| ROICReturn on invested capital | — | +0.6% | -145.5% | +9.9% | +6.5% |
| ROCEReturn on capital employed | — | +0.6% | -109.0% | +12.7% | +7.2% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 6 | 2 | 7 | 6 |
| Debt / EquityFinancial leverage | — | — | 2.97x | 0.10x | 1.73x |
| Net DebtTotal debt minus cash | $9M | -$404M | -$6M | $31M | $4.0B |
| Cash & Equiv.Liquid assets | $209,337 | $404M | $41M | $5M | $675M |
| Total DebtShort + long-term debt | $9M | $0 | $34M | $37M | $4.7B |
| Interest CoverageEBIT ÷ Interest expense | -4.34x | — | — | 77.08x | 2.84x |
Total Returns (Dividends Reinvested)
MKSI leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NPKI five years ago would be worth $19,150 today (with dividends reinvested), compared to $6 for BURU. Over the past 12 months, MKSI leads with a +306.1% total return vs LYRA's -91.6%. The 3-year compound annual growth rate (CAGR) favors MKSI at 54.1% vs BURU's -89.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -76.1% | +35.8% | -86.1% | +27.6% | +78.8% |
| 1-Year ReturnPast 12 months | -65.9% | +75.6% | -91.6% | +94.9% | +306.1% |
| 3-Year ReturnCumulative with dividends | -99.9% | -12.7% | -99.7% | +91.5% | +266.0% |
| 5-Year ReturnCumulative with dividends | -99.9% | -48.5% | -99.9% | +91.5% | +66.5% |
| 10-Year ReturnCumulative with dividends | -99.9% | +20.2% | -100.0% | +91.5% | +750.6% |
| CAGR (3Y)Annualised 3-year return | -89.2% | -4.4% | -85.0% | +24.2% | +54.1% |
Risk & Volatility
Evenly matched — LYRA and NPKI each lead in 1 of 2 comparable metrics.
Risk & Volatility
LYRA is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than MKSI's 2.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NPKI currently trades 93.5% from its 52-week high vs LYRA's 1.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.21x | 1.80x | 0.65x | 1.47x | 2.64x |
| 52-Week HighHighest price in past year | $4.24 | $155.82 | $37.50 | $16.50 | $326.83 |
| 52-Week LowLowest price in past year | $0.15 | $53.98 | $0.44 | $7.63 | $71.49 |
| % of 52W HighCurrent price vs 52-week peak | +5.6% | +65.2% | +1.2% | +93.5% | +92.0% |
| RSI (14)Momentum oscillator 0–100 | 47.7 | 39.7 | 22.3 | 56.6 | 65.3 |
| Avg Volume (50D)Average daily shares traded | 41.8M | 510K | 159K | 795K | 1.2M |
Analyst Outlook
IPGP leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: IPGP as "Buy", NPKI as "Buy", MKSI as "Buy". Consensus price targets imply 49.2% upside for IPGP (target: $152) vs -9.3% for MKSI (target: $273). MKSI is the only dividend payer here at 0.29% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | — | Buy | Buy |
| Price TargetConsensus 12-month target | — | $151.67 | — | — | $272.86 |
| # AnalystsCovering analysts | — | 27 | — | 3 | 29 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +0.3% |
| Dividend StreakConsecutive years of raises | — | 1 | — | 0 | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — | $0.87 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.3% | 0.0% | +1.7% | +0.2% |
NPKI leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MKSI leads in 1 (Total Returns). 2 tied.
BURU vs IPGP vs LYRA vs NPKI vs MKSI: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is BURU or IPGP or LYRA or NPKI or MKSI a better buy right now?
For growth investors, NPK International Inc.
(NPKI) is the stronger pick with 27. 4% revenue growth year-over-year, versus -92. 7% for Nuburu, Inc. (BURU). NPK International Inc. (NPKI) offers the better valuation at 36. 8x trailing P/E (29. 3x forward), making it the more compelling value choice. Analysts rate IPG Photonics Corporation (IPGP) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BURU or IPGP or LYRA or NPKI or MKSI?
On trailing P/E, NPK International Inc.
(NPKI) is the cheapest at 36. 8x versus IPG Photonics Corporation at 139. 2x. On forward P/E, NPK International Inc. is actually cheaper at 29. 3x.
03Which is the better long-term investment — BURU or IPGP or LYRA or NPKI or MKSI?
Over the past 5 years, NPK International Inc.
(NPKI) delivered a total return of +91. 5%, compared to -99. 9% for Nuburu, Inc. (BURU). Over 10 years, the gap is even starker: MKSI returned +750. 6% versus LYRA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BURU or IPGP or LYRA or NPKI or MKSI?
By beta (market sensitivity over 5 years), Lyra Therapeutics, Inc.
(LYRA) is the lower-risk stock at 0. 65β versus MKS Inc. 's 2. 64β — meaning MKSI is approximately 309% more volatile than LYRA relative to the S&P 500. On balance sheet safety, NPK International Inc. (NPKI) carries a lower debt/equity ratio of 10% versus 3% for Lyra Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — BURU or IPGP or LYRA or NPKI or MKSI?
By revenue growth (latest reported year), NPK International Inc.
(NPKI) is pulling ahead at 27. 4% versus -92. 7% for Nuburu, Inc. (BURU). On earnings-per-share growth, the picture is similar: NPK International Inc. grew EPS 124. 0% year-over-year, compared to -13. 5% for Lyra Therapeutics, Inc.. Over a 3-year CAGR, LYRA leads at 75. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BURU or IPGP or LYRA or NPKI or MKSI?
NPK International Inc.
(NPKI) is the more profitable company, earning 13. 0% net margin versus -226. 9% for Nuburu, Inc. — meaning it keeps 13. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NPKI leads at 16. 9% versus -86. 4% for BURU. At the gross margin level — before operating expenses — LYRA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BURU or IPGP or LYRA or NPKI or MKSI more undervalued right now?
On forward earnings alone, NPK International Inc.
(NPKI) trades at 29. 3x forward P/E versus 62. 6x for IPG Photonics Corporation — 33. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IPGP: 49. 2% to $151. 67.
08Which pays a better dividend — BURU or IPGP or LYRA or NPKI or MKSI?
In this comparison, MKSI (0.
3% yield) pays a dividend. BURU, IPGP, LYRA, NPKI do not pay a meaningful dividend and should not be held primarily for income.
09Is BURU or IPGP or LYRA or NPKI or MKSI better for a retirement portfolio?
For long-horizon retirement investors, Lyra Therapeutics, Inc.
(LYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65)). IPG Photonics Corporation (IPGP) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LYRA: -100. 0%, IPGP: +20. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BURU and IPGP and LYRA and NPKI and MKSI?
These companies operate in different sectors (BURU (Industrials) and IPGP (Technology) and LYRA (Healthcare) and NPKI (Energy) and MKSI (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: BURU is a small-cap quality compounder stock; IPGP is a small-cap quality compounder stock; LYRA is a small-cap quality compounder stock; NPKI is a small-cap high-growth stock; MKSI is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.